Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K. Iwamoto N, et al. Among authors: nakashima m. Mod Rheumatol. 2009;19(5):488-92. doi: 10.1007/s10165-009-0187-8. Epub 2009 Jul 4. Mod Rheumatol. 2009. PMID: 19578932
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
Aramaki T, Kawakami A, Iwamoto N, Fujikawa K, Kawashiri SY, Tamai M, Arima K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Furuyama M, Matsuoka N, Ueki Y, Ida H, Origuchi T, Aoyagi K, Eguchi K. Aramaki T, et al. Among authors: nakashima m. Mod Rheumatol. 2009;19(6):652-6. doi: 10.1007/s10165-009-0216-7. Mod Rheumatol. 2009. PMID: 19787419
Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor.
Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, Arima K, Nakamura H, Yamasaki S, Ida H, Kawakami A, Ueki Y, Matsuoka N, Nakashima M, Mizokami A, Kawabe Y, Mine M, Fukuda T, Eguchi K. Origuchi T, et al. Among authors: nakashima m. Mod Rheumatol. 2011 Jun;21(3):244-50. doi: 10.1007/s10165-010-0384-5. Epub 2010 Dec 29. Mod Rheumatol. 2011. PMID: 21188454
Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T, Aramaki T, Nakashima M, Fujikawa K, Tsukada T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A. Kita J, et al. Among authors: nakashima m, nakashima y. Mod Rheumatol. 2012 Apr;22(2):195-201. doi: 10.1007/s10165-011-0511-y. Epub 2011 Sep 6. Mod Rheumatol. 2012. PMID: 21898075 Clinical Trial.
The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population.
Migita K, Agematsu K, Masumoto J, Ida H, Honda S, Jiuchi Y, Izumi Y, Maeda Y, Uehara R, Nakamura Y, Koga T, Kawakami A, Nakashima M, Fujieda Y, Nonaka F, Eguchi K, Furukawa H, Nakamura T, Nakamura M, Yasunami M. Migita K, et al. Among authors: nakashima m. PLoS One. 2013;8(2):e55227. doi: 10.1371/journal.pone.0055227. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437051 Free PMC article.
Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
Iwamoto N, Fukui S, Umeda M, Nishino A, Nakashima Y, Suzuki T, Horai Y, Nonaka F, Okada A, Koga T, Kawashiri SY, Fujikawa K, Aramaki T, Ichinose K, Hirai Y, Tamai M, Nakamura H, Terada K, Nakashima M, Mizokami A, Origuchi T, Eguchi K, Ueki Y, Kawakami A. Iwamoto N, et al. Among authors: nakashima m, nakashima y. Mod Rheumatol. 2016 Sep;26(5):662-6. doi: 10.3109/14397595.2015.1129692. Epub 2016 Feb 16. Mod Rheumatol. 2016. PMID: 26708444
Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy.
Koga T, Okada A, Fukuda T, Hidaka T, Ishii T, Ueki Y, Kodera T, Nakashima M, Takahashi Y, Honda S, Horai Y, Watanabe R, Okuno H, Aramaki T, Izumiyama T, Takai O, Miyashita T, Sato S, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Origuchi T, Nakamura H, Aoyagi K, Eguchi K, Kawakami A; Japanese RA Patients with RRP Study Group. Koga T, et al. Among authors: nakashima m. Medicine (Baltimore). 2016 Apr;95(17):e3476. doi: 10.1097/MD.0000000000003476. Medicine (Baltimore). 2016. PMID: 27124044 Free PMC article. Clinical Trial.
Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
Kawashiri SY, Nishino A, Suzuki T, Nakashima Y, Horai Y, Ueki Y, Aramaki T, Fujikawa K, Nakashima M, Okada A, Migita K, Mizokami A, Matsuoka N, Mine M, Sakito S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Aoyagi K, Eguchi K, Kawakami A. Kawashiri SY, et al. Among authors: nakashima m, nakashima y. Clin Exp Rheumatol. 2016 Sep-Oct;34(5):808-812. Epub 2016 Jun 22. Clin Exp Rheumatol. 2016. PMID: 27384149
2,153 results